Bioatla, Inc. · NASDAQ:BCAB
Bioatla — Corporate Update (November 2022)
11 slides from Bioatla's corporate update, Nov 4, 2022
Slide 1: BA3011 Supplemental NSCLC and Sarcoma Data
Exhibit 99.1 BA3011 Supplemental NSCLC and Sarcoma Data 10/2022 1
Slide 2: AXL BA3011-002 Phase 2 Part 1 - Disposition as of October 2022
AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24 patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed yet 2 withdrawal of consent early, before the first scan 14 efficacy-evaluable patients* ORR: 5/14 (36%) 12 Non-Sq patients 2 Sq patie
Slide 3: BA3011 NSCLC – response rate
Phase 2 part 1 BA3011 NSCLC – response rate 60 57% 50% # Patients 50 42% Enrolled 24 40 36% Dosed / 0 scan 6 (3 combo) 30 Not yet dosed 2 25% W/D consent 2 20 Efficacy evaluable 14 10 0/2 5/14 5/12 4*/7 4*/8 1**/4 0 NSQ+SQ All NSQ NSQ NSQ NSQ BA3011 + SQ monotherapy monotherapy nivolumab PD-1 Failur
Slide 4: BA3011: Best Response in Phase 2 Non-Squamous Patients
BA3011: Best Response in Phase 2 Non-Squamous Patients Non-Squamous patients - Phase 2 only 1.8mg/kg Q2W 100 Preliminary Data 80 60 40 PD PD SD PD SD SD SD PR* PR PR CR PR* EGFR Failure 20 0 -20 -40 -60 ---Monotherapy ---Combination -80 nd *2 scan pending TmPS range 1% - 100% -100 Average prior line
Slide 5: BA3011 NSCLC: Safety and tolerability profile
BA3011 NSCLC: Safety and tolerability profile Phase 2 at the RP2D 1.8 mg/kg Q2W BA3011 + Opdivo Characteristic BA3011 (N=13) (N=9) Any Adverse Events (AEs) 11 (85%) 6 (67%) 1 Related AEs with CTCAE Grade 3 or 4 (31%) 2 (22%) ▪ No treatment-related deaths 2 4 2 Any related serious AEs 2 (15%)* 2 (22%
Slide 6: Topline Interim Analysis Results following BA3011 in refractory sarcoma subtypes
Phase 2 Part 1 Topline Interim Analysis Results following BA3011 in refractory sarcoma subtypes Advance Phase 2 Part 1 Interim Results P2 Part 2 Leiomyosarcoma Leiomyosarcoma; Evaluating (n=18)* PFS rate 12W 32% STS Synovial sarcoma Synovial Go – Label Pendi (n=5)* PFS rate 12W 54% Expansion ng Lipo
Slide 7: Undifferentiated Pleomorphic Sarcoma (UPS): Phase 1 & 2
Undifferentiated Pleomorphic Sarcoma (UPS): Phase 1 & 2 (1.8mg/kg; n=10) BioAtla Page 1 of 1 Protocol: BA3011-001 Figure 1.3.2.1.1 Progression-free Survival per Investigator Assessment for UPS Patients with TmPS or TcPS >= 70 in Change Target Lesion From Baseline (%) Progression-free Survival Phase
Slide 8: Osteosarcoma: Change in Target Lesion and Progression Free Survival
Osteosarcoma: Phase 2 Change in Target Lesion and Progression Free Survival (1.8mg/kg; n=6) BioAtla Page 1 of 1 Protocol: BA3011-001 Figure 1.3.1.9.1 Progression-free Survival per Investigator Assessment for Patients with BA3011 alone & in Combination with Nivolumab - Bone(Osterosarcoma) in Phase 2
Slide 9: Liposarcoma and Synovial sarcoma Progression Free Survival
Liposarcoma and Synovial sarcoma Phase 2 Progression Free Survival Synovial Sarcoma BioAtla Page 1 of 1 Liposarcoma Change Target Lesion From Baseline (%) Protocol: BA3011-001 BioAtla Page 1 of 1 BA3011 1.8mg/kg Q2W BA3011 1.8mg/kg Q2W Figure 1.3.1.6.1 Progression -Free Survival by AXL for Patients
Slide 10: BA3011 Sarcoma: Safety and Tolerability Profile
BA3011 Sarcoma: Safety and Tolerability Profile Phase 2 at the RP2D 1.8 mg/kg Q2W Overview Mecbo– BA3011 ▪ AEs consistent with MMAE-based toxicity, including: o Reversible myelosuppression Grade 1-2 (19%) o Transient liver enzyme elevation Constipation Grade 3-4 (1%) o Metabolic disturbances ▪ Few r
Slide 11: UPS – Part 2 of the Phase 2 study (potentially registrational)
UPS – Part 2 of the Phase 2 study (potentially registrational) • Written feedback received from the FDA to the proposed part 2 of the Phase 2 study design, including selection of primary endpoint (ORR) and size of the study (n=80) • FDA supportive of including a more intensive dosing arm • Protocol